Autologous Peripheral Blood Stem Cell Transplantation in Children with Refractory or Relapsed Lymphoma: Results of Children's Oncology Group Study A5962

Biology of Blood and Marrow Transplantation

Volumn 17, Issue 2, 2011, Pages 249-258

  Harris, Richard E ^a   Termuhlen, Amanda M ^b   Smith, Lynette M ^c   Lynch, James ^c   Henry, Michael M ^d   Perkins, Sherrie L ^e   Gross, Thomas G ^b   Warkentin, Phyllis ^f   Vlachos, Adrianna ^g   Harrison, Lauren ^h   Cairo, Mitchell S ^h  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c Data Center Children's Oncology Group Data Center   (United States)

^d PHOENIX CHILDREN'S HOSPITAL   (United States)

^e UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^f UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^g SCHNEIDER CHILDREN'S HOSPITAL   (United States)

^h Department of Medicine   (United States)

Author keywords

Autologous transplant; CBV; HL; Lymphoma; NHL; PBSCT

Indexed keywords

CARMUSTINE; CD34 ANTIGEN; CHROMIUM; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; METHYLPREDNISOLONE;

ADOLESCENT; APHERESIS; ARTICLE; CANCER REGRESSION; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; EVENT FREE SURVIVAL; HODGKIN DISEASE; HUMAN; LUNG TOXICITY; MAJOR CLINICAL STUDY; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROSPECTIVE STUDY;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HODGKIN DISEASE; HUMANS; LUNG DISEASES; LYMPHOMA, NON-HODGKIN; MALE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; REMISSION INDUCTION; SALVAGE THERAPY; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 79151485721     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.07.002     Document Type: Article

References (48)

1. Reiter A., Schrappe M., Ludwig W.D., et al. Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM group report. Blood 2000, 95:416-421.
2. Burkhardt B., Zimmermann M., Oschlies I., et al. The impact of age and gender on biology, clinical features and treatment outcome of non-Hodgkin lymphoma in childhood and adolescence. Br J Haematol 2005, 131:39-49.
3. Gerrard M., Cairo M.S., Weston C., et al. Excellent survival following two courses of COPAD chemotherapy in children and adolescents with resected localized B-cell non-Hodgkin's lymphoma: results of the FAB/LMB 96 international study. Br J Haematol 2008, 141:840-847.
4. Link M.P., Shuster J.J., Donaldson S.S., Berard C.W., Murphy S.B. Treatment of children and young adults with early-stage non-Hodgkin's lymphoma. N Engl J Med 1997, 337:1259-1266.
5. Reiter A., Schrappe M., Tiemann M., et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-Frankfurt-Munster Group Trial NHL-BFM 90. Blood 1999, 94:3294-3306.
6. Cairo M.S., Gerrard M., Sposto R., et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood 2007, 109:2736-2743.
7. Cairo M.S., Sposto R., Hoover-Regan M., et al. Childhood and adolescent large-cell lymphoma (LCL): a review of the Children's Cancer Group experience. Am J Hematol 2003, 72:53-63.
8. Brugieres L., Le Deley M.C., Rosolen A., et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol 2009, 27:897-903.
9. Lowe E.J., Sposto R., Perkins S.L., et al. Intensive chemotherapy for systemic anaplastic large cell lymphoma in children and adolescents: final results of Children's Cancer Group Study 5941. Pediatr Blood Cancer 2009, 52:335-339.
10. Patte C., Auperin A., Gerrard M., et al. Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients. Blood 2007, 109:2773-2780.
11. Cairo M.S., Sposto R., Perkins S.L., et al. Burkitt's and Burkitt-like lymphoma in children and adolescents: a review of the Children's Cancer Group experience. Br J Haematol 2003, 120:660-670.
12. Anderson J.R., Jenkin R.D., Wilson J.F., et al. Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Childrens Cancer Group. J Clin Oncol 1993, 11:1024-1032.
13. Kobrinsky N.L., Sposto R., Shah N.R., et al. Outcomes of treatment of children and adolescents with recurrent non-Hodgkin's lymphoma and Hodgkin's disease with dexamethasone, etoposide, cisplatin, cytarabine, and l-asparaginase, maintenance chemotherapy, and transplantation: Children's Cancer Group Study CCG-5912. J Clin Oncol 2001, 19:2390-2396.
14. Nachman J.B., Sposto R., Herzog P., et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. J Clin Oncol 2002, 20:3765-3771.
15. Donaldson S.S., Link M.P., Weinstein H.J., et al. Final results of a prospective clinical trial with VAMP and low-dose involved-field radiation for children with low-risk Hodgkin's disease. J Clin Oncol 2007, 25:332-337.
16. Hutchinson R.J., Fryer C.J., Davis P.C., et al. MOPP or radiation in addition to ABVD in the treatment of pathologically staged advanced Hodgkin's disease in children: results of the Children's Cancer Group Phase III Trial. J Clin Oncol 1998, 16:897-906.
17. Wimmer R.S., Chauvenet A.R., London W.B., Villaluna D., de Alarcon P.A., Schwartz C.L. APE chemotherapy for children with relapsed Hodgkin disease: a Pediatric Oncology Group trial. Pediatr Blood Cancer 2006, 46:320-324.
18. Schellong G., Dorffel W., Claviez A., et al. Salvage therapy of progressive and recurrent Hodgkin's disease: results from a multicenter study of the pediatric DAL/GPOH-HD study group. J Clin Oncol 2005, 23:6181-6189.
19. Bolwell B., Kalaycio M., Sobecks R., et al. Autologous hematopoietic cell transplantation non-Hodgkin's lymphoma: 100 month follow-up. Bone Marrow Transplant 2002, 29:673-679.
20. Bierman P.J., Anderson J.R., Freeman M.B., et al. High-dose chemotherapy followed by autologous hematopoietic rescue for Hodgkin's disease patients following first relapse after chemotherapy. Ann Oncol 1996, 7:151-156.
21. Robertson M.J., Abonour R., Hromas R., Nelson R.P., Fineberg N.S., Cornetta K. Augmented high-dose regimen of cyclophosphamide, carmustine, and etoposide with autologous hematopoietic stem cell transplantation for relapsed and refractory aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2005, 46:1477-1487.
22. Majhail N.S., Weisdorf D.J., Defor T.E., et al. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma. Biol Blood Marrow Transplant 2006, 12:1065-1072.
23. Horning S.J., Chao N.J., Negrin R.S., et al. High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. Blood 1997, 89:801-813.
24. Johnston L.J., Horning S.J. Autologous hematopoietic cell transplantation in Hodgkin's disease. Biol Blood Marrow Transplant 2000, 6:289-300.
25. Bradley M.B., Cairo M.S. Stem cell transplantation for pediatric lymphoma: past, present and future. Bone Marrow Transplant 2008, 41:149-158.
26. Jagannath S., Armitage J.O., Dicke K.A., et al. Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1989, 7:179-185.
27. Kessinger A., Bierman P.J., Vose J.M., Armitage J.O. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous peripheral stem cell transplantation for patients with relapsed Hodgkin's disease. Blood 1991, 77:2322-2325.
28. Reece D.E., Barnett M.J., Connors J.M., et al. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease. J Clin Oncol 1991, 9:1871-1879.
29. Sabloff M., Atkins H.L., Bence-Bruckler I., et al. A 15-year analysis of early and late autologous hematopoietic stem cell transplant in relapsed, aggressive, transformed, and nontransformed follicular lymphoma. Biol Blood Marrow Transplant 2007, 13:956-964.
30. Reece D.E., Connors J.M., Spinelli J.J., et al. Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 1994, 83:1193-1199.
31. Weaver C.H., Appelbaum F.R., Petersen F.B., et al. High-dose cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation in patients with lymphoid malignancies who have received dose-limiting radiation therapy. J Clin Oncol 1993, 11:1329-1335.
32. Wheeler C., Antin J.H., Churchill W.H., et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol 1990, 8:648-656.
33. Brice P., Bouabdallah R., Moreau P., et al. Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin's disease: analysis of 280 patients from the French registry. Societe Francaise de Greffe de Moelle. Bone Marrow Transplant 1997, 20:21-26.
34. Verdeguer A., Pardo N., Madero L., et al. Autologous stem cell transplantation for advanced Hodgkin's disease in children. Spanish group for BMT in children (GETMON), Spain. Bone Marrow Transplant 2000, 25:31-34.
35. Bureo E., Ortega J.J., Munoz A., et al. Bone marrow transplantation in 46 pediatric patients with non-Hodgkin's lymphoma. Spanish Working Party for Bone Marrow Transplantation in Children. Bone Marrow Transplant 1995, 15:353-359.
36. Brugieres L., Quartier P., Le Deley M.C., et al. Relapses of childhood anaplastic large-cell lymphoma: treatment results in a series of 41 children-a report from the French Society of Pediatric Oncology. Ann Oncol 2000, 11:53-58.
37. Burkhardt B., Reiter A., Landmann E., et al. Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the Berlin-Frankfurt-Muenster group. J Clin Oncol 2009, 27:3363-3369.
38. Griffin T.C., Weitzman S., Weinstein H., et al. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 2009, 52:177-181.
39. Fernandez H.F., Escalon M.P., Pereira D., Lazarus H.M. Autotransplant conditioning regimens for aggressive lymphoma: are we on the right road?. Bone Marrow Transplant 2007, 40:505-513.
40. Holmberg L.A., Maloney D., Bensinger W. Immunotherapy with rituximab/interleukin-2 after autologous stem cell transplantation as treatment for CD20+ non-Hodgkin's lymphoma. Clin Lymphoma Myeloma 2006, 7:135-139.
41. Akpek G., Ambinder R.F., Piantadosi S., et al. Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol 2001, 19:4314-4321.
42. Anderlini P., Acholonu S.A., Okoroji G.J., et al. Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response. Bone Marrow Transplant 2004, 34:511-514.
43. Anderson J.E., Litzow M.R., Appelbaum F.R., et al. Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience. J Clin Oncol 1993, 11:2342-2350.
44. Jones R.J., Ambinder R.F., Piantadosi S., Santos G.W. Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991, 77:649-653.
45. Claviez A., Canals C., Dierickx D., et al. Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin's lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. Blood 2009, 114:2060-2067.
46. Woessmann W., Peters C., Lenhard M., et al. Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents-a Berlin-Frankfurt-Munster group report. Br J Haematol 2006, 133:176-182.
47. Carella A.M., Cavaliere M., Lerma E., et al. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 2000, 18:3918-3924.
48. Cairo M.S., Geyer M.B., Harrison L., et al. Myeloablative (MAC) autologous stem cell transplantation (AutoSCT) followed by reduced Intensity (RIC) allogeneic stem cell transplantation (AlloSCT) in children, adolescents and young adults (CAYA) with poor risk Hodgkin's lymphoma (HL): induction of long term GVHL effect. Biol Blood Marrow Transplant 2010, 16:69. S181.